On 8 Nov 2014, Singapore-Sichuan Hi-Tech Innovation Park (SSCIP) co-organized the “China Medical Innovation Summit · 2014 Chengdu” forum with Chipscreen in Chengdu. Over 100 local and overseas influential decision makers of leading pharmaceutical and medical technology companies and organizations attended the discussion focused on “FDA, the New Regulation-Challenges, Opportunities and Inspiration to China’s Innovative Drugs on Late-stage Clinical Research”.
During this forum, Chipscreen President Dr. Lu Xianping, the forum’s initiator, indicated that the biomedical industry in Chengdu has a very strong foundation and all-rounded advantages. Chengdu’s interest in biomedical sciences innovation will keep increasing. Furthermore, Chengdu now has the software as well as the hardware capabilities to boost the innovative drugs “Made in Chengdu”. Mr. Yuan Zong Yong, Deputy Director of Chengdu Hi-Tech Zone (CDHT) Management Committee, then introduced the latest updates on CDHT’s biomedical industry and SSCIP. For many years, Chengdu has been persevering in an innovative path, employing CDHT as a base for heavy investments into the biomedical industry and fully utilizing the advantages of local resources, environment, human talent, etc. Today, Chengdu has reached the forefront in life sciences and biotechnology in some areas, on par with the highest international standards.
In the summit, Vice President of Sembcorp Development and Representative of SSCIP, Mr. Chong Joon Woon, joined three other important representatives to have an exclusive interview and panel discussion. Mr. Chong emphasized SSCIP’s overall strategy and industry positioning on biomedical sciences. He also introduced SSCIP’s recent intensive investment promotion activities in the US, and shared his positive review on Chengdu’s exciting biomedical sources industry.
Vice President of Sembcorp Development and Representative of SSCIP, Mr. Chong Joon Woon, in an exclusive interview (2nd from left).
About China Medical Innovation Summit
This forum was initiated by Chipscreen President Dr. Lu Xianping, and five other leading experts in the medical field. The objective was to have high-level discussions on fundamental topics like major industry strategy, technology, commerce and capital investment models, with more specialized topics including industry revamp, innovative strategy, win-win collaborations with international medical enterprises, etc-so as to enhance the exchange of capital, technology, human resources and programs between companies, for the overall development of the medical industry in China.
About Chipscreen
Chipscreen is a leading integrated biotech company specialized in discovery and development of novel small molecule pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas. Their core competence is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise.
For more information, please visit http://www.chipscreen.com/En
